Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04889716
Status:
RECRUITING
Last Update Posted:
2023-12-19
First Post:
2021-05-07
Brief Title:
CAR-T Followed by Bispecific Antibodies
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Study Overview
Official Title:
Phase II Study of Dual Targeting of CD19 and CD20 Antigens Using Sequential CD19-directed CAR-T Cells Followed by Mosunetuzumab or Glofitamab in Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphomas
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab Cohort 1 or obinutuzumab and glofitamab Cohort 2 when given after CAR genetically modified T cells The study is for patients who have already received a CAR T-cell infusion Some patients who join the study will receive mosunetuzumab other patients later in the study may receive a different experimental drug glofitamab in combination with obinutuzumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None